Bio

Nigel J. Clarke, PhD, is Chief Scientific Officer and Vice President of R&D at Quest Diagnostics, where he leads research and new technology development across the company’s Clinical Solutions franchises and Global Diagnostic Network, overseeing a $38M R&D budget, long-range strategy planning, due diligence, and partnerships with academic, pharmaceutical, and government stakeholders including NIH, NCI, CDC, and FDA.

Over more than two decades at Quest, Nigel has held roles including Chief Laboratory Officer and VP of R&D—with responsibility for regulatory and quality across all Quest laboratories—and VP of R&D for Core Diagnostics and Technology, where he directed R&D across infectious disease, endocrinology, cardiovascular, metabolism, neuroimmunology, toxicology, and mass spectrometry.

Nigel is widely recognized for pioneering the clinical translation of LC-MS/MS, leading the transition of steroid, vitamin D, and peptide hormone assays from immunoassay to mass spectrometry at scale.

Prior to Quest, he held positions at ActivX Biosciences and Schering-Plough Research Institute, following postdoctoral training in biomedical mass spectrometry at the Mayo Clinic and a PhD from the University of Kent at Canterbury. He is an inventor on more than 150 granted patents worldwide and has authored numerous publications and textbook chapters, including in the Tietz series.